Invitae (NVTAQ) Aktie Kurs

Invitae Corp is primarily active in the healthcare and biotechnology industries.

Invitae Corp's main competitors in the market include other genetic testing companies such as Myriad Genetics, Exact Sciences, and Natera.

Invitae Corp is a leading medical genetics company based in San Francisco, California. Founded in 2010, Invitae is focused on providing genetic information to empower patients and healthcare providers in making informed medical decisions. With a mission to bring comprehensive genetic information into mainstream medical practice, Invitae offers a wide range of genetic tests across various medical specialties. The company has rapidly grown through strategic acquisitions and partnerships, expanding its portfolio and capabilities. Invitae's commitment to innovative genetic testing solutions and its dedication to improving patient outcomes has made it a trusted name in the field of medical genetics.

Invitae Corp has achieved several significant milestones in its journey. The company successfully completed several strategic acquisitions, such as CombiMatrix, Good Start Genetics, and Clear Genetics, which have expanded their genetic testing offerings. Invitae Corp also established numerous partnerships with prominent organizations, including Biogen, Bristol Myers Squibb, and Genome Medical, to advance precision medicine research and development. Additionally, they launched a groundbreaking genetic testing platform, enabling fast and affordable genetic testing solutions. Invitae Corp's accomplishments signify their commitment to revolutionizing genetic testing and personalized medicine, positioning them as a key player in the industry.

Invitae Corp is primarily present in the United States.

Invitae Corp is guided by a set of core values and a strong corporate philosophy. The company is committed to providing high-quality genetic information to individuals, families, and healthcare providers. With a focus on patients and their needs, Invitae Corp aims to make genetic testing more accessible and affordable. They strive to deliver accurate results and ensure the information is understandable and actionable for all stakeholders. Invitae Corp also emphasizes collaboration and partnerships within the medical community to advance genetic knowledge and improve patient care. Through these values and their dedication to genetic information, Invitae Corp strives to empower people with the insights to make informed healthcare decisions.

15 analytikere vurderer i øjeblikket Invitae-aktien: 0 anbefaler køb, 6 hold og 9 salg. For 2026 forventer analytikere, at Invitae genererer omsætning på 614,60 Mio. USD og indtjening pr. aktie på -0,90 USD.

Invitae Analytikerens Kursmål 2026

Omregnet til den aktuelle valutakurs handles Invitae-aktien til 0,00 EUR (0,00 USD).

Invitae-aktien (NVTAQ) er noteret på 7 børser, herunder: NYSE (NVTA), London (0JDB.L), SIX (Zürich) (IV8.SW), Frankfurt (IV8.F), München (IV8.MU), Düsseldorf (IV8.DU).

Invitae Corp is a company specialized in providing genetic tests. Its business model consists of offering customers accurate insights into their DNA and helping them identify genetic risks or predispositions in order to make better health-related decisions. The company has a specialized laboratory that performs and analyzes genetic tests. Invitae conducts tests in various areas, such as oncology, neurology, and rare diseases. The company also offers a wide range of tests, ranging from preventive screenings to targeted diagnostic tests. To offer these tests, Invitae has built a platform that makes it easy to order genetic tests. Customers can order a test directly from home without needing a referral from a doctor. Patients can order either directly through Invitae's website or through a doctor if they prefer. The company also offers various products such as the "Invitae Carrier Screening," which investigates the transmission of genetic diseases from parents to their children. These tests can also help identify couples at high risk, optimize their genetic counseling, and assist them in family planning. Invitae also provides solutions for customers who have already undergone genetic tests and want to have their results analyzed. The company has developed specialized services that allow combining the results of different tests to provide customers with a comprehensive range of information. The company also partners with various companies and organizations to promote and sell its products and services. Its partners include major hospital systems, laboratories, and insurance companies. Invitae Corp focuses on offering genetic tests in multiple areas to maximize the benefits of genetic technology for patients. It has built an e-commerce platform that makes it easy for customers to order its products. Invitae also offers a wide range of tests covering various applications. With its innovative and comprehensive services, Invitae Corp has established itself as a leading company in the genetics industry.

forventet-omsætningen for Invitae er 614,60 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for Invitae er -247,87 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Invitae er i øjeblikket -0,00. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Invitae-aktien.

Pris-til-salgs-forholdet (P/S) for Invitae er i øjeblikket 0,00. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Invitae-aktien.

AlleAktien-kvalitetsscore for Invitae er 6/10.

ISIN for Invitae er US46185L1035. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Invitae er A14NKG. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Invitae er NVTAQ. Tickersymbolet bruges til at handle Invitae-aktier på børsen.